Role of translational research advancing the understanding of the pathogenesis of light chain-mediated glomerulopathies

Pathology International

Volumn 57, Issue 7, 2007, Pages 398-412

  Teng, Jiamin ^a   Turbat Herrera, Elba A ^a   Herrera, Guillermo A ^a  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

Author keywords

Amyloidosis; Glomerulopathies; Kidney; Light chain deposition disease; Light chains; Pathogenesis

Indexed keywords

CELL CULTURE; CELL GROWTH; CELL ISOLATION; ENDOPLASMIC RETICULUM; GLOMERULOPATHY; GLOMERULUS; HUMAN; IMMUNOGOLD LABELING; IN VITRO STUDY; IN VIVO STUDY; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY INJURY; LIGHT CHAIN; MESANGIUM; MESANGIUM CELL; NEPHRECTOMY; NONHUMAN; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE; ULTRASTRUCTURE;

AMYLOIDOSIS; ANIMALS; BIOMEDICAL RESEARCH; CELLS, CULTURED; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN KAPPA-CHAINS; KIDNEY GLOMERULUS; PARAPROTEINEMIAS;

EID: 34250819436     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2007.02116.x     Document Type: Review

References (98)

1. Herrera GA. Renal manifestations in plasma cell dyscrasias: An appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol 2000 4 : 174 200.
2. Herrera GA. Low molecular weight proteins and the kidney. Physiological and pathological considerations. Ultrastruct Pathol 1994 18 : 89 98.
3. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH. The spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991 64 : 527 37.
4. Sanders PW, Herrera GA. Monoclonal immunoglobulin light chain-related renal diseases. Semin Nephrol 1993 13 : 324 41.
5. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int 2005 68 : 1590 603.
6. Herrera GA, Russell WJ, Isaac J et al. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Ultrastruct Pathol 1999 23 : 107 26.
7. Keeling J, Dempsey S, Joseph L, Turbat-Herrera EA, Herrera GA. The role of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in mesangial matrix replacement in AL-amyloidosis: An in-vivo and in-vitro correlative study. In : Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis. Boca Raton : CRC Press, 2005 136 8.
8. Herrera GA, Welbourne TC, Russell WJ. Isolated perfused rat kidney: A new model to evaluate light chain nephrotoxicity (Abstract). Lab Invest 2001 81 : 188A.
9. Teng J, Hererra GA. Mesangial amyloid formation in an isolated kidney perfusion rat model: A new model to study renal amyloidogenesis (Abstract). Amyloid J Protein Folding Dis 2006 13 : 8.
10. Harper PA, Robinson JM, Hoover RL, Wright TC, Karnovsky MJ. Improved methods for culturing rat glomerular cells. Kidney Int 1984 26 : 875 80.
11. Teng J, Russell W, Gu X, Cardelli J, Jones ML, Herrera GA. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004 84 : 440 51.
12. Herrera GA, Sanders PW, Reddy BV, Hasbargen JA, Hammond WS, Brooke JD. Ultrastructural immunolabeling: A unique diagnostic tool in monoclonal light chain related renal diseases. Ultrastruct Pathol 1994 18 : 401 16.
13. Cole L, Davies D, Hyde GJ, Ashford AE. ER-Tracker dye and BODIPY-brefeldin A differentiate the endoplasmic reticulum and Golgi bodies from the tubular-vacuole system in living hyphae of Pisolithus tinctorius. J Microsc 2000 197 : 239 48.
14. Diwu Z, Lu Y, Zhang C, Klaubert DH, Haugland RP. Fluorescent molecular probes II. The synthesis, spectral properties and use of fluorescent solvatochromic dapoxyl dyes. Photochem Photobiol 1997 66 : 424 31.
15. Diwu Z, Zhang Y, Haugland RP. Novel site-selective fluorescent probes for lysosomes and acidic organelle staining and long-term tracking (Abstract). Cytometry 1994 7 : 1994.
16. Tagouri YM, Sanders PW, Picken MM, Siegal GP, Kerby JD, Herrera GA. In vitro AL-amyloid formation by rat and human mesangial cells. Lab Invest 1996 74 : 290 302.
17. Teng J, Herrera GA. Isolated kidney perfusion model to evaluate the role of caveolin-1 in glomerulopathic light chain-mesangial cell interactions. J Am Soc Nephrol 2006 17 : 649A.
18. Russell WJ, Cardelli J, Harris E, Baier RJ, Herrera GA. Monoclonal light chain-mesangial cell interactions: Early signaling events and subsequent pathologic effects. Lab Invest 2001 81 : 689 703.
19. Johnson RJ, Floege J, Yoshimura A, Lida H, Couser WG, Alpers CE. The activated mesangial cell: A glomerular 'myofibroblast'?. J Am Soc Nephrol 1992 2 : S190 97.
20. Herrera GA, Russell WJ, Cardelli J. Phenotypic transformation of mesangial cells precedes and is required for AL-amyloidogenesis. In : Bely M, Apathy A, eds. Amyloid and Amyloidosis. The Proceedings of the IXth International Symposium on Amyloidosis. Budapest : David Apathy, 2001 267 72.
21. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004 84 : 1322 38.
22. Adams W. Mollitis ossium. Trans Pathol Soc Lond 1872 23 : 186 8.
23. Magnus-Levy A. Bence-Jones-Eiseiss und Amyloid. Z Klin Med 1931 116 : 510 31.
24. Bell ET. Renal lesions associated with multiple myeloma. Am J Pathol 1933 9 : 393 419.
25. Sikl H. A case of diffuse plasmacytosis with deposition of protein crystals in the kidneys. J Pathol Bacteriol 1949 61 : 149 63.
26. Grabar P, Williams CA. Méthode permettant l'étude conjugée des propriétés électrophorétiques et immunochimiques d'un mélange de protéines: Application au sérum sanguine. Biochim Biophys Acta 1953 10 : 193 4.
27. Edelman GM, Gally JA. The nature of amyloid proteins. Chemical similarities to polypeptide chains of myeloma globulins and normal gamma globulins. J Exp Med 1962 116 : 207 27.
28. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science 1971 172 : 1150 51.
29. Linke RP, Zucker-Franklin D, Franklin EC. Morphologic, chemical and immunologic studies of amyloid-like fibrils formed from Bence Jones proteins proteolysis. J Immunol 1973 111 : 10 23.
30. Epstein WC, Tan M, Wood IS. Formation of 'amyloid' fibrils in vitro by action of human kidney lysosomal enzymes on Bence Jones proteins. J Lab Clin Med 1974 84 : 107 10.
31. Cohen AS. Electron microscopic observations on a fibrosis component in amyloid of diverse origins. Nature 1959 183 : 1202 3.
32. Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest 1972 51 : 2773 6.
33. Jaffé RH. Amyloidosis produced by injections of proteins. Arch Pathol Lab Med 1926 1 : 25 36.
34. Shirahama T, Cohen AS. An analysis of the close relationship of lysosomes to early deposits of amyloid. Am J Pathol 1973 73 : 97 114.
35. Shirahama T, Cohen AS. Intralysosomal formation of amyloid fibrils. Am J Pathol 1975 81 : 101 16.
36. Shirahama T, Cohen AS. Fine structure of the glomerulus in human and experimental amyloidosis. Am J Pathol 1967 51 : 869 911.
37. von Gise H, Christ H, Bohle A. Early glomerular lesions in amyloidosis. Electron microscopic findings. Virchows Arch A Pathol Anat Histol 1981 390 : 259 72.
38. Kisilevsky R. Amyloids: Tombstones or triggers?. Nat Med 2000 6 : 633 4.
39. Cameron JS. Conclusions. In : Minetti L, D'Amico G, Ponticelli C, eds. The Kidney in Plasma Cell Dyscrasias. Dordrecht : Kluwer Academic Publishers, 1988 291 9.
40. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991 324 : 1845 51.
41. Isaac J, Kerby J, Russell W, Dempsey SC, Sanders PW, Herrera GA. In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid Int J Exp Clin Invest 1998 5 : 238 46.
42. Tagouri YM, Sanders PW, Zhu L et al. Glomerulopathic monoclonal light chains potentiate mesangial cell apoptosis in vitro (Abstract). Lab Invest 1995 92 : 161A.
43. Kobernick SD, Whiteside JH. Renal glomerulus in multiple myeloma. Lab Invest 1957 6 : 478 85.
44. Abrahams C, Pirani CL, Pollak VE. Ultrastructure of the kidney in a patient with multiple myeloma. J Pathol Bacteriol 1966 92 : 220 25.
45. Antonovych TT, Lin RC, Mostofi FK. Light chain deposits in multiple myeloma. Ultrastructural and immunofluorescence findings in the kidney. Lab Invest 1974 30 : 370A.
46. Randall RE, Williamson WC, Mullinax F, Tung MY, Still WJS. Manifestations of systemic light chain deposition. Am J Med 1976 60 : 293 9.
47. Herrera GA, Shultz J, Soong S, Sanders PW. Growth factors in monoclonal light chain related renal diseases. Hum Pathol 1994 25 : 883 92.
48. Truong LD, Pindur J, Barrios R et al. Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int 1994 45 : 201 10.
49. Turbat-Herrera EA, Isaac J, Sanders PW, Truong LD, Herrera GA. Integrated expression of glomerular extracellular matrix proteins and α1-integrins in monoclonal light chain-related renal diseases. Mod Pathol 1997 10 : 485 95.
50. Roberts AB, McCune BK, Sporn MB. TGF-β: Regulation of extracellular matrix. Kidney Int 1992 41 : 557 9.
51. Border W, Okuda S, Nakamura T. Extracellular matrix and glomerular disease. Semin Nephrol 1989 9 : 307 17.
52. Ronco PMAM-A, Mougenot B, Aucouturier P. Light chain deposition disease: A model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001 12 : 1558 65.
53. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang ZQ, Sanders PW. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-β. Am J Pathol 1995 147 : 375 85.
54. Border WA, Ruoslahti E. Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 1992 90 : 1 7.
55. Kopp JB, Factor VM, Mozes M et al. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest 1996 74 : 991 1003.
56. Raghow B, Irish P, Kang AH. Coordinate regulation of transforming growth factor-β gene expression and cell proliferation in hamster lungs undergoing bleomycin-induced pulmonary fibrosis. J Clin Invest 1991 84 : 1836 42.
57. Broeckelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor-β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991 88 : 6642 6.
58. Shah MD, Foreman M, Ferguson WJ. Control of scarring in adult wounds by neutralizing antibody to transforming growth factor β. Lancet 1992 339 : 213 14.
59. Sakamura T, Kusano I. Tenascin in tissue perturbation repair. Acta Pathol Jpn 1991 41 : 247 58.
60. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995 147 : 1759 69.
61. Teng J, Zhang PL, Russell WJ, Zheng LP, Herrera GA. Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains. Nephron Physiol 2003 94 : 28 38.
62. Teng J, Moriyama T, Herrera GA. Curcumin by inhibiting TGF-β cascade in human mesangial cells decreases extracellular matrix production by fibrogenic light chains (Abstract). J Am Soc Nephrol 2005 116 : 663A.
63. Gaedeke J, Noble N, Border WA. Curcumin blocks multiple sites of the TFG-β signaling cascade in renal cells. Kidney Int 2004 66 : 112 20.
64. Moriyama T, Teng J, Herrera GA. Caveolin-1 plays a fundamental signaling role in mesangial cells incubated with glomerulopathic light chains (Abstract). J Am Soc Nephrol 2005 16 : 376A.
65. Lai HC, Chao WT, Chen YT, Yang VC. Effect of EGCG, a major component of green tea, on the expression of Ets-1, c-Fos and c-Jun during angiogenesis in vitro. Cancer Lett 2004 213 : 181 8.
66. Weber A-A, Neuhaus T, Skach RA et al. Mechanisms of the inhibitory effect of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis. FASEB J 2004 18 : 128 30.
67. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999 19 : 1589 92.
68. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999 274 : 21 91 4.
69. Herrera GA. Plasticity of mesangial cells: A basis for understanding pathological alterations. Ultrastruct Pathol 2006 30 : 345 53.
70. El Nahas AM. Plasticity of kidney cells. Role in kidney remodeling and scarring. Kidney Int 2003 64 : 1553 63.
71. Davies M, Martin J, Thomas GJ, Lovett DH. Proteinases and glomerular matrix turnover. Kidney Int 1992 41 : 671 8.
72. Muller D, Roessner A, Rocken C. Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and α2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch 2000 437 : 521.
73. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1 -2, and -3. Am J Pathol 2001 159 : 561 70.
74. Truong LD, Majesky M, Pindur J. Tenascin is synthesized and secreted by rat mesangial cells in culture and is present in extracellular matrix in human glomerular diseases. J Am Soc Nephrol 1994 4 : 1771 7.
75. Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 1994 352 : 216 18.
76. Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chain of immunoglobulins. Preferential association of the λ VI subgroup of human light chains with amyloidosis AL. J Clin Invest 1982 70 : 453 60.
77. Comenzo RL, Zhang Y, Martinez C et al. The tropism of organ involvement in primary systemic amyloidosis: Contributions of Ig VL germ line gene use and clonal plasma cell burden. Blood 2001 98 : 714 20.
78. Stevens FJ, Pokkuluri PR, Schiffer M. Protein conformation and disease: Pathological consequences of analogous mutations in homologous proteins. Biochemistry 2000 39 : 15 91 6.
79. Pokkuluri PR, Solomon A, Weiss DT, Stevens FJ, Schiffer M. Tertiary structure of human lambda 6 light chains. Amyloid Int J Exp Clin Invest 1999 6 : 165 71.
80. Wall JS, Gupta V, Wilkerson M et al. Structural basis of light chain amyloidogenicity: Comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four V (lambda) 6 proteins. J Mol Recognit 2004 17 : 323 31.
81. Stevens FJ. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid Int J Clin Exp Invest 2000 7 : 200 11.
82. Omtvedt LA, Husby G, Cornwell GG, Kyle RA, Sletten K. The amino acid sequence of the glycosylated amyloid immunoglobulin light chain protein AL MS. Scand J Immunol 1997 45 : 551 6.
83. Omtvedt LA, Bailey D, Renouf DV et al. Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid Int J Exp Clin Invest 2000 7 : 227 44.
84. Bellotti V, Mangione P, Merlini G. Review: Immunoglobulin light chain amyloidosis: The archetype of structural and pathogenic variability. J Struct Biol 2000 130 : 280 89.
85. Denoroy L, Deret S, Aucouturier P. Overreprresentation of the VkIV subgroup in light chain deposition disease. Immunol Lett 1994 42 : 63 6.
86. Khamlichi AA, Aucouturier P, Silvain C et al. Primary structure of a monoclonal kappa chain in (FRA) myeloma with light chain deposition disease. Clin Exp Immunol 1992 87 : 122 6.
87. Decourt C, Touchard G, Preud'homme J-L et al. Complete primary sequences of two {lambda} immunoglobulin light chains in myelomas with nonamyloid (Randall-Type) light chain deposition disease. Am J Pathol 1998 153 : 313 18.
88. Belloti V, Stoppini M, Merlini G et al. Amino acid sequence of κ Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. Biochim Biophys Acta 1991 1097 : 177 82.
89. Khamlichi AA, Rocca A, Touchard G, Aucouturier P, Preud'homme JL, Cogne M. Role of light chain variable region in myeloma with light chain deposition disease: Evidence from an experimental model. Blood 1995 86 : 3655 9.
90. Rocca A, Klamlichi AA, Aucouturier P et al. Primary structure of a variable region of the Vκl subgroup (ISE) in light chain deposition disease. Clin Exp Immunol 1993 91 : 506 9.
91. Solomon A, Weiss DT. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid Int J Exp Clin Invest 1995 2 : 26 79.
92. Hmcic R, Wall J, Wolfenbarger DA et al. Antibody-mediated resolution of light chain associated amyloid deposits. Am J Pathol 2000 157 : 1239 46.
93. Little MH. Regrow or repair. Potential regenerative therapies for the kidney. J Am Soc Nephrol 2006 17 : 2390 401.
94. Poulsom R, Alison MR, Cook HT et al. Bone marrow stem cells contribute to healing of the kidney. J Am Soc Nephrol 2003 14 : S48 54.
95. Imasawa T, Utsunomiya Y, Kawamura T et al. The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol 2001 12 : 1401 9.
96. Kunter U, Rong S, Djuric Z et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006 17 : 2202 12.
97. Zerbini G, Piemonti L, Maestroni A, Dell'Antonio G, Bianchi G. Stem cells and the kidney: A new therapeutic tool?. J Am Soc Nephrol 2006 17 : S123 6.
98. Rabelink TJ, van-Kooten C. Stem cell therapy for glomerular disease. J Am Soc Nephrol 2006 17 : 2086 8.